Public Health Today—April 24, 2026
This weekly Public Health update highlights key developments across policy,…
Obesity Today—April 7, 2026
This week’s Obesity update highlights regulatory progress, advancing late-stage…
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1 asset
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1……
Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide collaboration
Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide…
Lucid Diligence Brief: Hims & Hers to acquire Eucalyptus
Lucid Diligence Brief: Hims & Hers to acquire Eucalyptus Professional…
Lucid Diligence Brief: AstraZeneca and CSPC obesity and T2D collaboration
Lucid Diligence Brief: AstraZeneca and CSPC obesity and T2D collaboration…
Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development
Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development…
Obesity Video Recap—January 20, 2026
This biweekly Obesity video recap covers a mix of late-stage regulatory…
AI in Healthcare and Digital Health Video Recap —January 12, 2026
Here’s your AI in Healthcare and Digital Health video brief covering recent…
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A Professional…
Obesity Video Recap—January 5, 2026
This Obesity video recap highlights major Phase 3 readouts, new regulatory…
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity candidates
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity……